Fatigue Workup in Childbearing Women: Not a Fishing Trip

Four tests. That’s the starting line: CBC, ferritin, TSH, pregnancy test. Not a 30-tube rainbow draw.

“I'm just so tired all the time.” It's one of the most common complaints in primary care, and in women of childbearing age, the differential is simultaneously broad and predictable. The temptation is to order everything—a CMP, CBC, iron studies, B12, folate, vitamin D, cortisol, ANA, Lyme, EBV, celiac panel, ferritin, TSH, free T4, testosterone—and hope something lights up. That's not a workup. That's a fishing trip. And fishing trips catch incidental abnormalities that generate more tests, more anxiety, and no answers.

This post makes the case for a disciplined, stepwise approach.

The Core Four: Start Here, Every Time

The First-Line Panel

1. CBC: Anemia is the most common lab-identifiable cause of fatigue in this population. Look at hemoglobin AND MCV (microcytic = iron deficiency until proven otherwise).
2. Ferritin: Iron deficiency causes fatigue before anemia develops. A normal hemoglobin does NOT rule out iron deficiency. Ferritin is the test that catches the pre-anemic state.
3. TSH: Hypothyroidism is common in women of reproductive age. One test, high yield.
4. Pregnancy test (urine hCG): Fatigue is often the first symptom of early pregnancy, before a missed period is noticed. In any woman of childbearing age with new-onset fatigue, rule it out. It changes everything about your workup and management.

These four tests cover the most common and most treatable causes of fatigue in this population. If all four are normal, then you expand.

Iron Deficiency Without Anemia: The Under-Recognized Entity

This is the clinical pearl that separates a good fatigue workup from a mediocre one. Iron deficiency exists on a spectrum:

• Stage 1: Depleted iron stores (low ferritin, normal hemoglobin, normal MCV). The patient is symptomatic—fatigued, brain fog, exercise intolerance, restless legs—but the CBC is “normal.”
• Stage 2: Iron-deficient erythropoiesis (low ferritin, low transferrin saturation, normal or borderline hemoglobin, possibly low MCV)
• Stage 3: Iron deficiency anemia (low ferritin, low hemoglobin, low MCV, microcytic hypochromic RBCs on smear)

If you only check a CBC and the hemoglobin is 12.5, you'll call it normal and send the patient home. But her ferritin might be 8. She has iron deficiency without anemia—and she'll feel dramatically better with iron replacement.

The Ferritin Threshold Debate

What ferritin level defines iron deficiency? This is more contentious than it should be.

• WHO/traditional cutoff: Ferritin <15 ng/mL = iron deficiency
• Most hematologists and current evidence: Ferritin <30 ng/mL = iron deficiency in the context of symptoms
• Functional iron deficiency (especially with inflammation): Ferritin <100 ng/mL with transferrin saturation <20% may indicate iron deficiency despite “normal” ferritin (ferritin is an acute phase reactant)

For a symptomatic woman of childbearing age, ferritin <30 should be treated as iron deficiency. Multiple RCTs have demonstrated symptom improvement with iron supplementation in non-anemic women with ferritin <50, particularly for fatigue and cognitive function.

When the Core Four Are Normal: Expanding the Workup

Tier 2 (If Core Four Are Normal and Fatigue Persists >4 Weeks)

• BMP: Electrolyte abnormalities (hyponatremia, hypercalcemia), renal insufficiency, glucose (diabetes or hypoglycemia)
• Vitamin D: Deficiency is endemic but its role in fatigue is debated. Check it, but manage expectations—correcting vitamin D may or may not resolve fatigue.
• Depression screening (PHQ-9): This should arguably be Tier 1. Depression and fatigue are intimately linked, and no lab test diagnoses depression. If the PHQ-9 is positive, treat the depression.
• Sleep history: Obstructive sleep apnea is underdiagnosed in women. Ask about snoring, witnessed apneas, morning headaches. STOP-BANG questionnaire.

Tier 3 (If Tier 2 Normal and Specific Symptoms Suggest)

• Celiac panel (tTG-IgA + total IgA): If GI symptoms, iron-refractory iron deficiency, or family history
• ANA: Only if joint pain, rash, photosensitivity, or other autoimmune features are present. Do NOT order ANA as a fishing expedition—the false positive rate in young women is high, and it generates referrals and anxiety without answers.
• Cortisol (AM): Only if Addisonian features (orthostasis, hyperpigmentation, salt craving, weight loss)
• EBV panel: Only if acute-onset fatigue with pharyngitis, lymphadenopathy, splenomegaly. Chronic EBV is not a validated diagnosis; don't order it for chronic fatigue.
• B12/MMA: Lower yield in this population (more relevant for elderly, vegans, post-bariatric surgery)

What NOT to Order (and Why)

Choosing Wisely for Fatigue

• Lyme titers in non-endemic areas: False positives abound. Only test if exposure history + clinical features support it.
• EBV titers for chronic fatigue: Most adults are EBV seropositive. A positive IgG means past exposure, not active disease. It doesn't explain chronic fatigue.
• ANA without autoimmune features: Up to 20% of healthy young women have low-titer positive ANA. A positive ANA without clinical findings generates rheumatology referrals that end with “no autoimmune disease.”
• Morning cortisol without Addisonian features: Random cortisol testing for fatigue has extremely poor specificity. Adrenal insufficiency is rare; poor sleep, depression, and iron deficiency are common.
• Testosterone levels in premenopausal women: Not validated as a fatigue workup tool in this population.
• “Adrenal fatigue” panels: This is not a recognized medical diagnosis. Salivary cortisol panels marketed for “adrenal fatigue” are not evidence-based.

When Labs Are Normal: What Then?

If the Core Four are normal, depression is screened for, sleep is addressed, and Tier 2 labs are unrevealing, the most common diagnoses remaining are:

• Depression/anxiety (may need formal psychiatric evaluation if PHQ-9 doesn't capture it)
• Sleep deprivation (the most undertreated cause of fatigue in working mothers)
• Obstructive sleep apnea (consider sleep study)
• Chronic fatigue syndrome / ME/CFS: Diagnosis of exclusion. Requires ≥6 months of unexplained fatigue + post-exertional malaise + unrefreshing sleep. Validate the patient's experience.
• Lifestyle factors: Overcommitment, caregiving burden, inadequate nutrition, deconditioning

The most important thing at this stage is to believe the patient. “Your labs are normal” doesn't mean “you're fine.” It means the labs didn't find the answer. The fatigue is real.

Iron Replacement: Practical Notes

• Oral iron: Ferrous sulfate 325 mg (65 mg elemental iron) every other day is better absorbed than daily (hepcidin rebound with daily dosing). Take with vitamin C, empty stomach, avoid calcium/coffee/tea within 2 hours.
• IV iron: Consider for ferritin <15 with Hgb <10, oral intolerance, malabsorption (celiac, IBD, bariatric surgery), second/third trimester pregnancy with significant anemia, or failure to respond to 4–6 weeks of oral iron.
• Recheck ferritin at 8–12 weeks. Goal: ferritin >50 (some argue >100 for sustained repletion).
• Identify the source: Heavy menstrual bleeding is the most common cause of iron deficiency in this population. Screen with pictorial bleeding assessment chart (PBAC) or menstrual history. If HMB is present, treat the bleeding (hormonal management, referral to GYN) in addition to replacing iron.

Bottom Line

Fatigue in childbearing women is best approached with discipline, not a shotgun. Start with CBC, ferritin, TSH, and a pregnancy test. Ferritin <30 in a symptomatic woman is iron deficiency regardless of hemoglobin. If the Core Four are normal, screen for depression and sleep disorders before adding labs. Don't order ANA, EBV, or cortisol without specific clinical indications. And when all the labs come back normal, the fatigue is still real—acknowledge it, investigate further, and keep advocating for your patient.

Stay sharp out there.

Tumor Markers in Primary Care: When to Order, When to Step Away, and Why Screening Causes More Harm Than Good

 

Tumor Markers in Primary Care: When to Order, When to Step Away, and Why Screening Causes More Harm Than Good

PSA, CA-125, CEA, AFP—the tests that cause the most unnecessary panic in your practice.

Tumor markers are among the most misused tests in primary care. They get ordered for vague abdominal pain, pelvic discomfort, fatigue, or "just to be thorough"—and then a mildly elevated result triggers imaging, referrals, biopsies, and patient anxiety for a condition that doesn't exist. The core principle: tumor markers are for monitoring known cancers, not for screening asymptomatic patients (with limited exceptions).

The Markers: What They Do and Don't Tell You

Marker	Primary Cancer Association	Non-Cancer Causes of Elevation	Role in Primary Care
PSA	Prostate cancer	BPH, prostatitis, recent ejaculation, bike riding, UTI, age	Screening (shared decision-making for men 55–69); monitoring after treatment
CA-125	Ovarian cancer	Endometriosis, fibroids, PID, pregnancy, menstruation, cirrhosis, CHF, peritonitis, any peritoneal/pleural inflammation	Monitoring known ovarian cancer. NOT for screening pelvic pain.
CEA	Colorectal cancer	Smoking (most common), IBD, pancreatitis, cirrhosis, peptic ulcer, hypothyroidism	Monitoring colorectal cancer post-treatment. NOT for screening.
AFP	Hepatocellular carcinoma, germ cell tumors	Pregnancy, hepatitis, cirrhosis (regenerating nodules)	HCC surveillance in cirrhosis patients (with ultrasound every 6 months). Germ cell tumor monitoring.
CA 19-9	Pancreatic cancer	Biliary obstruction, cholangitis, pancreatitis, cirrhosis. Not expressed in Lewis antigen-negative patients (~5–10%).	Monitoring known pancreatic cancer. NOT for screening abdominal pain.
HCG	Gestational trophoblastic disease, germ cell tumors	Pregnancy (obviously), marijuana use (rarely), pituitary HCG production in postmenopausal women	Monitoring trophoblastic disease and germ cell tumors post-treatment.

The Rules That Prevent Harm

1. CA-125 Is NOT a Screening Test for Ovarian Cancer

This is the most commonly violated rule. CA-125 is elevated in roughly 80% of advanced ovarian cancer but only 50% of early-stage disease. Meanwhile, it's elevated in dozens of benign conditions: endometriosis, fibroids, PID, menstruation, pregnancy, and any cause of peritoneal or pleural inflammation. The USPSTF recommends against screening for ovarian cancer (including CA-125 and transvaginal ultrasound) in average-risk women because screening does not reduce mortality and leads to unnecessary surgeries, some with serious complications.

The Harm

Ordering CA-125 for "pelvic pain" in a premenopausal woman will frequently return a mildly elevated result from endometriosis, a corpus luteum cyst, or menstruation—triggering imaging, surgical consultation, and sometimes unnecessary oophorectomy. Do not order CA-125 as a screening test in average-risk women. It is appropriate for monitoring response in known ovarian cancer or evaluating a suspicious adnexal mass in a postmenopausal woman in conjunction with imaging.

2. PSA: Shared Decision-Making, Not Reflexive Ordering

Per USPSTF (2018, reaffirmed): for men 55–69, PSA screening should be an individual decision made after shared decision-making about benefits and harms. Not recommended for men ≥70 or men with <10-year life expectancy. Key points:

• PSA >4 ng/mL is traditionally considered the threshold, but many cancers occur below 4 and many benign conditions elevate PSA above 4.
• PSA velocity (rate of change) and PSA density (PSA relative to prostate volume) improve specificity.
• For screening, discuss overdiagnosis and overtreatment. Many screen-detected prostate cancers are low-grade and would never cause symptoms or death.

3. CEA Doesn't Screen for Colorectal Cancer

CEA is only useful for monitoring known CRC post-resection (rising levels may indicate recurrence). Smokers commonly have elevated CEA without cancer. It should never be ordered as a CRC screening test—colonoscopy and stool-based tests (FIT, Cologuard) are the appropriate screens.

4. AFP Has a Defined Surveillance Role

AFP plus abdominal ultrasound every 6 months is the recommended HCC surveillance strategy in patients with cirrhosis (any etiology) and chronic hepatitis B without cirrhosis who meet risk criteria. Outside of this specific surveillance context, AFP should not be ordered for vague abdominal symptoms.

The Pitfalls

• Ordering tumor markers for nonspecific symptoms: This creates false-positive results, unnecessary imaging, invasive follow-up procedures, and patient anxiety—without improving outcomes.
• Using tumor markers to diagnose cancer: Tumor markers support diagnosis in the right clinical context but are NEVER diagnostic on their own. Tissue biopsy is required.
• Not knowing the non-cancer causes: Every tumor marker has a long list of benign elevations. If you don't know the list, you'll over-investigate every positive.
• Ordering panels: "Tumor marker panels" that include CA-125, CEA, CA 19-9, AFP, and CA 15-3 together are almost never indicated in primary care. They generate a statistically inevitable false positive and do not improve cancer detection.
• Repeating tumor markers as "follow-up" without oncology guidance: Post-treatment tumor marker surveillance should be directed by the oncology team, not primary care guesswork.

Bottom Line

Tumor markers are monitoring tools, not screening tools (with the narrow exceptions of PSA with shared decision-making and AFP in cirrhosis surveillance). Ordering them for nonspecific symptoms is one of the most reliably harmful testing decisions in primary care. Know what each marker does, know its benign causes, and resist the urge to order a "cancer panel" for reassurance. The reassurance it provides is false, and the anxiety it generates is real.

Stay sharp out there.